[{"id":"04d8f3c7-64bd-44c3-be44-47d8879d4d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832892","created_at":"2023-04-27T14:05:02.983Z","updated_at":"2024-07-02T16:34:26.014Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05832892","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • CTLA4 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • erfonrilimab (KN046) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-14"},{"id":"7d35f15f-f2de-4fad-9cce-09c440f911d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652283","created_at":"2022-12-15T14:58:15.323Z","updated_at":"2024-07-02T16:35:05.706Z","phase":"Phase 2","brief_title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","source_id_and_acronym":"NCT05652283","lead_sponsor":"Bai-Rong Xia","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2022","start_date":" 11/06/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-06"},{"id":"918ddae7-2ff1-4ee0-9113-6762c5e8dfb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579757","created_at":"2021-01-18T21:51:28.003Z","updated_at":"2024-07-02T16:35:19.961Z","phase":"Phase 1/2","brief_title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04579757","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-02-09"},{"id":"01d93d84-ceb8-4d89-9e96-016cb7325fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05481463","created_at":"2022-08-01T15:55:26.976Z","updated_at":"2024-07-02T16:35:29.397Z","phase":"Phase 2","brief_title":"Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05481463","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-11-13"},{"id":"1e30bc94-6063-438f-88ab-1406ca5f477b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04653480","created_at":"2021-01-19T20:41:06.787Z","updated_at":"2024-07-02T16:35:42.871Z","phase":"Phase 2","brief_title":"Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC","source_id_and_acronym":"NCT04653480","lead_sponsor":"Zhejiang University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-17"},{"id":"a918b622-1695-4ae4-8aaf-74e22d538627","acronym":"","url":"https://clinicaltrials.gov/study/NCT05746728","created_at":"2023-02-28T13:01:14.764Z","updated_at":"2024-07-02T16:35:51.316Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer","source_id_and_acronym":"NCT05746728","lead_sponsor":"Huihua Xiong","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 expression • ER expression • PARP1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ER expression • PARP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-04-06"},{"id":"98d97099-58b6-42c8-a565-6a53ad427d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05186545","created_at":"2022-01-11T15:56:04.181Z","updated_at":"2024-07-02T16:36:04.549Z","phase":"Phase 2","brief_title":"An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer","source_id_and_acronym":"NCT05186545","lead_sponsor":"The First Affiliated Hospital of Zhengzhou University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Epidaza (chidamide) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-09-02"},{"id":"785cf943-f46d-41b5-a744-2198e88473ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05165407","created_at":"2021-12-21T15:53:36.458Z","updated_at":"2024-07-02T16:36:19.281Z","phase":"Phase 2","brief_title":"Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC","source_id_and_acronym":"NCT05165407","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Sulanda (surufatinib) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2021-12-21"}]